IP Library Granted Patent US 11,046,955
Granted Patent B2
US 11,046,955 · App. 15/568,650 · Granted Jun 29, 2021

Modified AAV constructs and uses thereof

Inventors: Guangping Gao (Westborough, MA); Jun Xie (Shrewsbury, MA); Phillip D. Zamore (Northborough, MA)
Assignee: University of Massachusetts
C12N15/113A61K31/713C12N15/111C12N15/86C12N2310/11C12N2310/141C12N2310/531C12N2330/51C12N2750/14143C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,955
App. No.
15/568,650
Granted
Jun 29, 2021
Kind
B2
Abstract

The present disclosure relates to the field of rAAV delivery of transgenes. In some aspects, the disclosure relates to RNAi. Provided herein are recombinant adeno-associated virus (rAAV) vectors comprising modified ITRs. In some embodiments, the modified ITRs comprise a sequence encoding a shRNA, miRNA, or AmiRNA.

Claims (10)

1. A self-complementary AAV (scAAV) viral genome comprising wild-type inverted terminal repeats (ITRs) at each of two ends and an inner portion comprising a sequence encoding a hairpin-forming RNA, wherein the sequence encoding the hairpin-forming RNA replaces a mutant ITR normally present in a scAAV viral genome, and wherein the scAAV viral genome is capable of producing recombinant adeno-associated viral particles.

2. The self-complementary AAV (scAAV) viral genome of claim 1 , wherein the sequence encoding the hairpin-forming RNA is operably linked with a promoter.

3. The self-complementary AAV (scAAV) viral genome of claim 1 , wherein the sequence encoding a hairpin-forming RNA forms a shRNA, miRNA, or AmiRNA, wherein the AmiRNA construct comprises:

(i) a nucleic acid sequence encoding a pri-miRNA scaffold;

(ii) a nucleic acid sequence encoding a guide strand; and,

(iii) a nucleic acid sequence encoding a passenger strand,

wherein the pri-miRNA scaffold is derived from a naturally-occurring pri-miRNA and comprises at least one flanking sequence and a loop forming sequence comprising at least 4 nucleotides.

4. The self-complementary AAV (scAAV) viral genome of claim 3 , wherein the nucleic acid sequence encoding the guide strand and the nucleic acid sequence encoding the passenger strand have at least one base pair mismatch, optionally wherein at least one base pair mismatch is located at an anchor position or in a center portion of a stem.

5. The self-complementary AAV (scAAV) viral genome of claim 3 , wherein the pri-miRNA scaffold is derived from a pri-miRNA selected from the group consisting of pri-MIR-21, pri-MIR-22, pri-MIR-26a, pri-MIR-30a, pri-MIR-33, pri-MIR-122, pri-MIR-375, pri-MIR-199, pri-MIR-99, pri-MIR-194, pri-MIR-155, and pri-MIR-451.

6. The self-complementary AAV (scAAV) viral genome of claim 3 , wherein the guide strand targets a gene associated with a gain of function mutation disease, an oncogene, or a gene associated with a metabolic disorder, optionally wherein the guide strand targets SOD1, Huntington gene, p53, HER2/neu, LDLR, or beta-glucosidase.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: ZAMORE, PHILLIP D.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 046483/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: GAO, GUANGPING; XIE, JUN; ZAMORE, PHILLIP D.; HOWARD HUGHES MEDICAL INSTITUTE
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 046483/0962 →
Continuity (2)
Provisional Application 62152602 · Apr 24, 2015
Related Publication 20180298380A1 · Oct 18, 2018
Cited By (1)
US 12,371,710